Article
Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Apr 2020
Lin G, Li C, Li P S, Fang W Z, Xu H P, Gong Y H, Zhu Z F, Hu Y, Liang W H, Chu Q, Zhong W Z, Wu L, Wang H J, Wang Z J, Li Z M, Lin J, Guan Y F, Xia X F, Yi X, Miao Q, Wu B, Jiang K, Zheng X B, Zhu W F, Zheng X L, Huang P S, Xiao W J, Hu D, Zhang L F, Fan X R, Mok T S K, Huang C
Abstract excerpt
BACKGROUND: Adenosquamous carcinoma (ASC) of the lung is a heterogeneous disease that is composed of both adenocarcinoma components (ACC) and squamous cell carcinoma components (SCCC). Their genomic profile, genetic origin, and clinical management remain controversial. PATIENTS AND METHODS: Resected ASC and metastatic tumor in regional lymph nodes (LNs) were collected. The ACC and SCCC were separated by...
Topics
- Carcinoma, Adenosquamous
- China
- ErbB Receptors
- Genomics
- Humans
- Lung Neoplasms
- Mutation
- Protein Kinase Inhibitors
- Retrospective Studies